Big Pharma Mega Deals in the Last Few Months Series Part 4 | Respiratory and Infectious Disease: From COPD and Rare Lung Disorders to Seasonal Viral Threats
Alongside oncology and metabolic disease, one of the most striking clusters in recent big pharma transactions over the last few months is respiratory and infectious disease. Chronic obstructive pulmonary disease (COPD), asthma, rare lung...
